CN1671660A - 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮-单乙烷磺酸盐及其作为药物组合物的用途 - Google Patents
3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮-单乙烷磺酸盐及其作为药物组合物的用途 Download PDFInfo
- Publication number
- CN1671660A CN1671660A CNA038175304A CN03817530A CN1671660A CN 1671660 A CN1671660 A CN 1671660A CN A038175304 A CNA038175304 A CN A038175304A CN 03817530 A CN03817530 A CN 03817530A CN 1671660 A CN1671660 A CN 1671660A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- carbonyl
- methoxycarbonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
h | k | l | 2Θ[°] | dhkl值[] | 强度[%] |
0 | 0 | 1 | 7.70 | 11.47 | 17.7 |
0 | -1 | 0 | 8.78 | 10.07 | 19.2 |
-1 | 0 | 1 | 9.47 | 9.33 | 26.4 |
1 | 0 | 1 | 9.82 | 9.00 | 32.2 |
2 | 0 | 0 | 11.59 | 7.63 | 30.9 |
0 | -2 | 1 | 11.93 | 7.41 | 26.3 |
1 | 2 | 0 | 13.15 | 6.73 | 29.6 |
-2 | 0 | 1 | 13.69 | 6.47 | 31.8 |
2 | 1 | 0 | 14.17 | 6.24 | 30.9 |
3 | -1 | 0 | 16.32 | 5.43 | 41.7 |
0 | 1 | 2 | 16.72 | 5.30 | 29.0 |
-1 | 1 | 2 | 16.92 | 5.238 | 9.8 |
3 | 0 | 0 | 17.43 | 5.08 | 42.7 |
2 | 2 | 0 | 17.77 | 4.99 | 26.9 |
1 | -4 | 0 | 18.58 | 4.77 | 31.1 |
-3 | 0 | 1 | 18.81 | 4.71 | 41.8 |
-2 | 0 | 2 | 19.03 | 4.66 | 39.2 |
3 | -3 | 1 | 19.73 | 4.50 | 40.2 |
0 | 4 | 0 | 19.87 | 4.47 | 6.2 |
2 | -4 | 1 | 20.03 | 4.43 | 100.0 |
0 | -4 | 1 | 20.61 | 4.31 | 8.3 |
-3 | -1 | 1 | 20.83 | 4.26 | 5.5 |
1 | 2 | 2 | 21.26 | 4.18 | 31.1 |
-1 | 3 | 2 | 21.76 | 4.08 | 19.8 |
0 | 4 | 1 | 22.05 | 4.03 | 32.4 |
3 | -4 | 1 | 22.19 | 4.00 | 10.1 |
0 | 3 | 2 | 22.57 | 3.94 | 25.6 |
-3 | 4 | 1 | 23.10 | 3.85 | 32.3 |
-1 | 0 | 3 | 23.81 | 3.73 | 32.0 |
1 | 4 | 1 | 24.69 | 3.60 | 26.6 |
1 | 3 | 2 | 24.78 | 3.58 | 24.6 |
0 | 3 | 0 | 24.91 | 3.572 | 15.6 |
-1 | 5 | 1 | 25.42 | 3.50 | 23.7 |
-4 | 4 | 1 | 26.24 | 3.39 | 24.8 |
3 | -2 | 2 | 26.91 | 3.31 | 22.9 |
-3 | 4 | 2 | 27.19 | 3.28 | 23.9 |
1 | 5 | 0 | 27.61 | 3.23 | 22.0 |
-1 | -5 | 1 | 27.95 | 3.19 | 22.3 |
3 | -1 | 3 | 28.71 | 3.11 | 22.1 |
5 | 0 | 0 | 29.25 | 3.05 | 20.2 |
化学式 | C66H78N10O15S2 |
分子量 | 1315.52 |
结晶系统 | 三斜晶系 |
a | 16.332 |
b | 19.199 |
c | 11.503 |
α | 95.27° |
β | 90.13° |
γ | 110.83° |
V | 3354.4A3 |
结构解析 | 来自单晶数据 |
空间基团 | P1(#2) |
密度(经估计的) | 2.605克/公分3 |
单元内容 | >2分子的不同的构型>2×EtSO4>1×H2O |
Claims (13)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10233500.1 | 2002-07-24 | ||
DE10233500A DE10233500A1 (de) | 2002-07-24 | 2002-07-24 | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1671660A true CN1671660A (zh) | 2005-09-21 |
CN100351235C CN100351235C (zh) | 2007-11-28 |
Family
ID=30469050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038175304A Ceased CN100351235C (zh) | 2002-07-24 | 2003-07-18 | 2-吲哚满酮-单乙磺酸盐及其制备药物组合物的用途 |
Country Status (36)
Country | Link |
---|---|
US (2) | US7119093B2 (zh) |
EP (2) | EP2386543A1 (zh) |
JP (1) | JP5039279B2 (zh) |
KR (1) | KR101145691B1 (zh) |
CN (1) | CN100351235C (zh) |
AR (2) | AR040662A1 (zh) |
AT (1) | ATE551322T1 (zh) |
AU (1) | AU2003254376B2 (zh) |
BR (1) | BRPI0312811B8 (zh) |
CA (1) | CA2493310C (zh) |
CY (1) | CY1112916T1 (zh) |
DE (1) | DE10233500A1 (zh) |
DK (1) | DK1527047T3 (zh) |
EA (1) | EA008684B1 (zh) |
EC (1) | ECSP055571A (zh) |
EG (1) | EG24562A (zh) |
ES (1) | ES2384968T3 (zh) |
HK (1) | HK1078851A1 (zh) |
HR (1) | HRP20050070B1 (zh) |
IL (2) | IL166405A0 (zh) |
ME (1) | ME00353B (zh) |
MX (1) | MXPA04012785A (zh) |
MY (1) | MY136883A (zh) |
NO (1) | NO330486B1 (zh) |
NZ (1) | NZ538367A (zh) |
PE (1) | PE20040704A1 (zh) |
PL (1) | PL223758B1 (zh) |
PT (1) | PT1527047E (zh) |
RS (1) | RS52283B (zh) |
SA (1) | SA03240446B1 (zh) |
SI (1) | SI1527047T1 (zh) |
TW (1) | TWI285635B (zh) |
UA (1) | UA78352C2 (zh) |
UY (1) | UY27904A1 (zh) |
WO (1) | WO2004013099A1 (zh) |
ZA (1) | ZA200409814B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102334030A (zh) * | 2009-03-12 | 2012-01-25 | 贝林格尔.英格海姆国际有限公司 | 利用生物标记监测疗法之方法或系统 |
CN104003925A (zh) * | 2013-06-05 | 2014-08-27 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
CN105001143A (zh) * | 2015-07-24 | 2015-10-28 | 南京正大天晴制药有限公司 | 一种制备高纯度乙磺酸尼达尼布的方法 |
CN106432042A (zh) * | 2015-08-13 | 2017-02-22 | 南京华威医药科技开发有限公司 | 尼达尼布乙磺酸水合物的药物新晶型 |
CN102056598B (zh) * | 2008-06-06 | 2017-09-19 | 勃林格殷格翰国际有限公司 | 含有吲哚满酮衍生物悬浮液制剂的胶囊药物剂型 |
WO2017198202A1 (zh) * | 2016-05-19 | 2017-11-23 | 上海诚妙医药科技有限公司 | 尼达尼布的新晶型及其制备方法及其用途 |
CN107428686A (zh) * | 2015-03-13 | 2017-12-01 | 正大天晴药业集团股份有限公司 | 尼达尼布二乙磺酸盐晶体及其制备方法和用途 |
CN111848490A (zh) * | 2020-08-24 | 2020-10-30 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
CN113024439A (zh) * | 2021-03-28 | 2021-06-25 | 郑州大学 | 尼达尼布乙磺酸盐新晶型ⅰ的制备 |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
US20040204458A1 (en) * | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
EP1870400A1 (en) * | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
JP5385268B2 (ja) | 2007-06-21 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インドリン−2−オンおよびアザ−インドリン−2−オン |
PE20091445A1 (es) * | 2007-12-03 | 2009-10-19 | Boehringer Ingelheim Int | Derivados de indolinona y procedimiento para su fabricacion |
DK2229359T3 (en) * | 2007-12-03 | 2018-02-05 | Boehringer Ingelheim Int | Process for preparing an indolinone derivative |
SI2293795T1 (sl) * | 2008-06-06 | 2015-12-31 | Boehringer Ingelheim International Gmbh | Farmacevtska kombinacija |
US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
WO2010081817A1 (en) | 2009-01-14 | 2010-07-22 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
US20120142703A1 (en) | 2009-05-14 | 2012-06-07 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
EP2429527A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of cancer and fibrotic diseases |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
WO2012068441A2 (en) | 2010-11-19 | 2012-05-24 | Ratiopharm Gmbh | Intedanib salts and solid state forms thereof |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
JP2015524400A (ja) | 2012-07-19 | 2015-08-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 9−[4−(3−クロロ−2−フルオロ−フェニルアミノ)−7−メトキシ−キナゾリン−6−イルオキシ]−1,4−ジアザ−スピロ[5.5]ウンデカン−5−オンのフマル酸塩、その薬物としての使用及び調製 |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
EP2914622B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
WO2015009889A1 (en) * | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
JP6799201B2 (ja) | 2013-07-31 | 2020-12-16 | アヴァリン ファーマ インク. | エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用 |
US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
CN105126909B (zh) * | 2015-07-13 | 2018-01-23 | 淮海工学院 | 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用 |
WO2017077551A2 (en) * | 2015-11-03 | 2017-05-11 | Mylan Laboratories Limited | An amorphous nintedanib esylate and solid dispersion thereof |
CZ2016104A3 (cs) | 2016-02-24 | 2017-09-06 | Zentiva, K.S. | Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy |
EP3442534A1 (en) * | 2016-04-13 | 2019-02-20 | Boehringer Ingelheim International GmbH | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer |
EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
JP2019522638A (ja) | 2016-05-27 | 2019-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ニンテダニブ及びピルフェニドンによる治療開始を判定するためのecmバイオマーカーの使用 |
EP3463353A1 (en) | 2016-06-01 | 2019-04-10 | Boehringer Ingelheim International GmbH | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
ITUA20164213A1 (it) * | 2016-06-08 | 2017-12-08 | Olon Spa | Polimorfo di nintedanib |
EP3515444A4 (en) | 2016-09-26 | 2020-06-03 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION |
US20200069679A1 (en) | 2016-12-12 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol |
US10981896B2 (en) * | 2017-03-02 | 2021-04-20 | Board Of Regents, The University Of Texas System | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase |
WO2018165865A1 (zh) * | 2017-03-14 | 2018-09-20 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 |
TWI632133B (zh) * | 2017-03-15 | 2018-08-11 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型 |
TWI676617B (zh) * | 2017-03-15 | 2019-11-11 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型 |
CN110573161A (zh) | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
WO2019048974A1 (en) * | 2017-09-06 | 2019-03-14 | Glenmark Pharmaceuticals Limited | PROCESS FOR PREPARING NINTEDANIB |
EA202090977A1 (ru) | 2017-10-23 | 2020-09-04 | Бёрингер Ингельхайм Интернациональ Гмбх | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) |
EP3710427B1 (en) | 2017-11-17 | 2023-03-08 | Fermion Oy | Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib |
IL277146B2 (en) | 2018-03-07 | 2024-02-01 | Pliant Therapeutics Inc | Amino acid compounds and methods of use |
CN116808044A (zh) | 2018-06-15 | 2023-09-29 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
CN109988094B (zh) * | 2019-04-29 | 2020-04-14 | 石药集团中奇制药技术(石家庄)有限公司 | 一种乙磺酸尼达尼布的制备方法 |
WO2021110805A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
CA3179187A1 (en) | 2020-05-22 | 2021-11-25 | Qx Therapeutics Inc. | Compositions and methods for treating lung injuries associated with viral infections |
AU2021321561A1 (en) * | 2020-08-07 | 2023-03-09 | Bdr Lifesciences Private Limited | An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof |
EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
KR20240042322A (ko) | 2022-09-23 | 2024-04-02 | 삼아제약 주식회사 | 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB395546A (en) | 1931-10-12 | 1933-07-20 | Robert Pauli Scherer | Method of and apparatus for making capsules |
US2720463A (en) | 1950-11-17 | 1955-10-11 | American Cyanamid Co | Gelatin capsule casting composition preparation |
US2870062A (en) | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
DE3579384D1 (de) | 1984-07-24 | 1990-10-04 | Scherer Gmbh R P | Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung. |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
CA2379021C (en) * | 1999-08-23 | 2009-10-27 | Solvay Pharmaceuticals B.V. | New phenylpiperazines |
US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
DE19949209A1 (de) * | 1999-10-13 | 2001-04-19 | Boehringer Ingelheim Pharma | In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10117204A1 (de) * | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
-
2002
- 2002-07-24 DE DE10233500A patent/DE10233500A1/de not_active Withdrawn
-
2003
- 2003-07-18 UA UAA200501637A patent/UA78352C2/uk unknown
- 2003-07-18 RS YU20050046A patent/RS52283B/sr unknown
- 2003-07-18 ES ES03766212T patent/ES2384968T3/es not_active Expired - Lifetime
- 2003-07-18 SI SI200332162T patent/SI1527047T1/sl unknown
- 2003-07-18 MX MXPA04012785A patent/MXPA04012785A/es active IP Right Grant
- 2003-07-18 CN CNB038175304A patent/CN100351235C/zh not_active Ceased
- 2003-07-18 BR BRPI0312811A patent/BRPI0312811B8/pt active IP Right Grant
- 2003-07-18 EP EP11172210A patent/EP2386543A1/en not_active Withdrawn
- 2003-07-18 IL IL16640503A patent/IL166405A0/xx unknown
- 2003-07-18 EA EA200500146A patent/EA008684B1/ru active Protection Beyond IP Right Term
- 2003-07-18 AT AT03766212T patent/ATE551322T1/de active
- 2003-07-18 AU AU2003254376A patent/AU2003254376B2/en active Active
- 2003-07-18 EP EP03766212A patent/EP1527047B1/en not_active Expired - Lifetime
- 2003-07-18 JP JP2004525239A patent/JP5039279B2/ja not_active Expired - Lifetime
- 2003-07-18 CA CA2493310A patent/CA2493310C/en not_active Expired - Lifetime
- 2003-07-18 WO PCT/EP2003/007822 patent/WO2004013099A1/en active Application Filing
- 2003-07-18 ME MEP-2008-537A patent/ME00353B/me unknown
- 2003-07-18 KR KR1020057001207A patent/KR101145691B1/ko active IP Right Grant
- 2003-07-18 NZ NZ538367A patent/NZ538367A/en not_active IP Right Cessation
- 2003-07-18 PL PL372996A patent/PL223758B1/pl unknown
- 2003-07-18 PT PT03766212T patent/PT1527047E/pt unknown
- 2003-07-18 DK DK03766212.9T patent/DK1527047T3/da active
- 2003-07-21 US US10/623,971 patent/US7119093B2/en not_active Expired - Lifetime
- 2003-07-22 MY MYPI20032748A patent/MY136883A/en unknown
- 2003-07-22 PE PE2003000728A patent/PE20040704A1/es active IP Right Grant
- 2003-07-22 EG EG2003070712A patent/EG24562A/xx active
- 2003-07-23 AR AR20030102633A patent/AR040662A1/es not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2003-07-23 UY UY27904A patent/UY27904A1/es not_active Application Discontinuation
- 2003-07-23 TW TW092120101A patent/TWI285635B/zh active
- 2003-12-16 SA SA03240446A patent/SA03240446B1/ar unknown
-
2004
- 2004-12-03 ZA ZA200409814A patent/ZA200409814B/xx unknown
-
2005
- 2005-01-20 IL IL166405A patent/IL166405A/en active IP Right Grant
- 2005-01-21 HR HRP20050070AA patent/HRP20050070B1/hr not_active IP Right Cessation
- 2005-01-24 EC EC2005005571A patent/ECSP055571A/es unknown
- 2005-02-23 NO NO20050985A patent/NO330486B1/no not_active IP Right Cessation
- 2005-11-24 HK HK05110630A patent/HK1078851A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 US US11/460,677 patent/US20060258681A1/en not_active Abandoned
-
2012
- 2012-06-13 CY CY20121100538T patent/CY1112916T1/el unknown
-
2013
- 2013-12-20 AR ARP130104954A patent/AR094217A2/es not_active Application Discontinuation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102056598B (zh) * | 2008-06-06 | 2017-09-19 | 勃林格殷格翰国际有限公司 | 含有吲哚满酮衍生物悬浮液制剂的胶囊药物剂型 |
CN102334030A (zh) * | 2009-03-12 | 2012-01-25 | 贝林格尔.英格海姆国际有限公司 | 利用生物标记监测疗法之方法或系统 |
CN104003925A (zh) * | 2013-06-05 | 2014-08-27 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
WO2014194795A1 (zh) * | 2013-06-05 | 2014-12-11 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
CN104003925B (zh) * | 2013-06-05 | 2016-03-30 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
CN107428686A (zh) * | 2015-03-13 | 2017-12-01 | 正大天晴药业集团股份有限公司 | 尼达尼布二乙磺酸盐晶体及其制备方法和用途 |
CN105001143A (zh) * | 2015-07-24 | 2015-10-28 | 南京正大天晴制药有限公司 | 一种制备高纯度乙磺酸尼达尼布的方法 |
CN106432042A (zh) * | 2015-08-13 | 2017-02-22 | 南京华威医药科技开发有限公司 | 尼达尼布乙磺酸水合物的药物新晶型 |
WO2017198202A1 (zh) * | 2016-05-19 | 2017-11-23 | 上海诚妙医药科技有限公司 | 尼达尼布的新晶型及其制备方法及其用途 |
CN109415314A (zh) * | 2016-05-19 | 2019-03-01 | 上海诚妙医药科技有限公司 | 尼达尼布的新晶型及其制备方法及其用途 |
CN111848490A (zh) * | 2020-08-24 | 2020-10-30 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
CN113024439A (zh) * | 2021-03-28 | 2021-06-25 | 郑州大学 | 尼达尼布乙磺酸盐新晶型ⅰ的制备 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100351235C (zh) | 2-吲哚满酮-单乙磺酸盐及其制备药物组合物的用途 | |
CN105753872B (zh) | 二螺吡咯烷衍生物 | |
CN103664958B (zh) | 一种替卡格雷的晶型及其制备方法 | |
WO2018214886A1 (zh) | 一种氘代azd9291的晶型、制备方法及用途 | |
CN1835951A (zh) | 选择性cdk4抑制剂的羟乙基磺酸盐 | |
WO2019001425A1 (zh) | 一种氘代奥斯替尼衍生物及其应用 | |
CN110483486A (zh) | 一种奥西替尼酮咯酸盐晶型及其制备方法 | |
CN106279127B (zh) | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 | |
CN113717245B (zh) | 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用 | |
CN1714098A (zh) | β-L-2'-脱氧胸苷的结晶形及非晶形 | |
CN104725380B (zh) | 卢索替尼的氘代衍生物 | |
CN111423438A (zh) | 具有抗肿瘤活性的Eudistomins Y类衍生物及其制备方法和应用 | |
CN104220420A (zh) | 一种长效β-2肾上腺素受体激动剂的新型多晶 | |
JP2022517396A (ja) | Egfr阻害剤の塩、結晶形及びその製造方法 | |
TWI825811B (zh) | 噻唑並內醯胺並螺雜環類化合物及其應用 | |
TW201219034A (en) | A potassium salt of substituted cycloalkene derivatives | |
CN107987092A (zh) | 苯并咪唑并噻唑乙酰胺类化合物及其应用 | |
WO2023241507A1 (zh) | 一种炔基吡啶类化合物的晶型及其制备方法 | |
TW200404787A (en) | Bis-arylsulfones | |
CN103214486A (zh) | β-咔啉衍生物或可药用盐,其制备方法及其抗肿瘤的应用 | |
CN103664738B (zh) | 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物 | |
CN114751858A (zh) | 含有喹啉基的氨甲环酸衍生物及其制备与应用 | |
CN104045614A (zh) | (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型c及其制备方法和应用 | |
CN109369531A (zh) | 一种新晶型的抗肿瘤化合物及其制备方法和含其的组合物 | |
CN107540602A (zh) | 拉西地平化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1078851 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1078851 Country of ref document: HK |
|
IW01 | Full invalidation of patent right | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20200319 Decision number of declaring invalidation: 43646 Granted publication date: 20071128 |
|
CI03 | Correction of invention patent | ||
CI03 | Correction of invention patent |
Correction item: whole invalidation of patent right Correct: Announcement of invalidation of all patent rights False: Announcement of total invalidation of patent right Number: 48-02 Volume: 36 |